Axsome Therapeutics (AXSM) Capital Expenditures (2015 - 2026)
Axsome Therapeutics (AXSM) reported Capital Expenditures of $121000.0 for Q1 2026, down 64.2% on a YoY basis from $338000.0 in Q1 2025, and up 70.42% sequentially from $71000.0 in Q4 2025.
Axsome Therapeutics (AXSM) Capital Expenditures (2015 - 2026) Analysis & Trends
Axsome Therapeutics (AXSM) has 12 years of Capital Expenditures data on file, last reported at $121000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 64.2% year-over-year to $121000.0; the trailing twelve-month figure through Mar 2026 stood at $263000.0 (down 48.43% YoY), and the FY2025 full-year result was $480000.0, up 77.78% from the prior year.
- Capital Expenditures climbed to $121000.0 in Q1 2026, from $71000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $371000.0 in Q3 2023 to a low of $7000.0 in Q4 2023.
- A 5-year average of $126764.7 and a median of $90000.0 in 2024 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures soared 40033.04% in 2022 and slumped 96.13% in 2023, its largest moves.
- Tracing AXSM's Capital Expenditures over 5 years: stood at $181000.0 in 2022, then tumbled by 96.13% to $7000.0 in 2023, then soared by 328.57% to $30000.0 in 2024, then soared by 136.67% to $71000.0 in 2025, then jumped by 70.42% to $121000.0 in 2026.
- Business Quant data shows AXSM's Capital Expenditures at $121000.0 in Q1 2026, $71000.0 in Q4 2025, and $58000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,462.92 Bn | 67,462.64 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,941.00 Bn | 1,940.94 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.07 Bn | 468.27 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 123.28 Bn | 116.03 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 70.12 Bn | 61.37 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.40 Bn | 62.40 Bn | - | - |
| 8 | Argenx Se | 56.45 Bn | 51.27 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Axsome Therapeutics | 12.33 Bn | 12.03 Bn | 176.48 Mn | 121,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 121,000.00 |
| Mar 31, 2026 | 121,000.00 |
| Dec 31, 2025 | 71,000.00 |
| Dec 31, 2025 | 71,000.00 |
| Sep 30, 2025 | 58,000.00 |
| Sep 30, 2025 | 58,000.00 |
| Jun 30, 2025 | 13,000.00 |
| Jun 30, 2025 | 13,000.00 |
| Mar 31, 2025 | 338,000.00 |
| Mar 31, 2025 | 338,000.00 |
| Dec 31, 2024 | 30,000.00 |
| Dec 31, 2024 | 30,000.00 |
| Sep 30, 2024 | 90,000.00 |
| Sep 30, 2024 | 90,000.00 |
| Jun 30, 2024 | 52,000.00 |
| Jun 30, 2024 | 52,000.00 |
| Mar 31, 2024 | 98,000.00 |
| Mar 31, 2024 | 98,000.00 |
| Dec 31, 2023 | 7,000.00 |
| Dec 31, 2023 | 7,000.00 |